Utrecht University, TNO, Novartis, Proefdiervrij, Cell4Pharma and AZAR Innovations have joined forces to create a drug disposition on a chip model for in vitro ADME/PK assessment.
In drug development, most Absorption, Distribution, Metabolism and Excretion (ADME) assessments are typically performed in animal models that can differ quite drastically from humans. A plethora of in vitro models, including microphysiological models based on human tissues or cells, have been developed with limited success. This is due to the fact that a simple static model (one without flow) based on a single organ or cell system does not accurately reflect the complex interactions between different organs involved in drug disposition.
To overcome these limitations, the consortium partners propose to develop a dynamic ‘drug disposition on-a-chip’ platform by combining and connecting the most relevant human organs associated with drug disposition, such as the intestine, the liver (including bile duct) and the kidney, through microfluidics and computational modeling.
There are four main steps for implementation. First, the individual organ chips (liver, kidney, intestine, bile duct) need to be created by immobilizing the corresponding cell types. Second, these organ chips need to be interconnected with fluidic devices. In the third step, the functionality of the interconnected organ-on-a-chip devices need to be validated with sets of pharmaceutical drugs with known pharmacokinetic behaviour. Finally, verification is needed to show that the drug disposition in humans could be efficiently modelled with readouts from this newly developed system.
Azar Innovations is committed to help this project with technical advice to connect advanced gut, liver and kidney models in a microphysiological system. Visit here to go to the news about this project.
Interested to know more about this project or our organ on a chip services? Contact us!